TLR8 agonist partially improves IFN-γ deficiency of NK cells in chronic hepatitis B through the synergy of monocytes

Aliment Pharmacol Ther. 2023 Feb;57(4):387-398. doi: 10.1111/apt.17382. Epub 2022 Dec 31.

Abstract

Background: Natural killer (NK) cells exhibit a selective deficiency of IFN-γ production in chronic hepatitis B (CHB). Toll-like receptor 8 (TLR8) agonists could induce IFN-γ production in immune cells, although their effects on the deficiency in NK cells remain unclear.

Aims: To investigate TLR8 expression in NK cells and the effect of TLR8 agonists in patients with CHB METHODS: We enrolled 32 patients with CHB and 19 healthy controls to assess TLR8 expression and IFN-γ production in NK cells. The sorted NK cells and monocytes were co-cultured to compare the extent of IFN-γ and IL-10 production after TLR8 agonist ssRNA40 stimulation. The synergic effect of NK cells and monocytes was assessed by blocking IL-12 and IL-18. We recruited another 22 patients with CHB undergoing nucleotide analogue (NA) therapy to explore the impact of antiviral treatment on the ssRNA40-mediated response of NK cells.

Results: In patients with CHB, TLR8 expression in NK cells was up-regulated, accompanied by insufficient IFN-γ production. The enhanced IFN-γ secretion by ssRNA40 in NK cells depended on monocyte-derived IL-12 and IL-18. NK cells displayed an imbalanced response to ssRNA40 in patients with CHB with a weak increase in IFN-γ despite a higher IL-10 production. The response was improved in patients with CHB undergoing NA therapy.

Conclusions: In patients with CHB, targeting TLR8 partially rescues the IFN-γ insufficiency in NK cells. However, NK cells show an inhibitory response to TLR8 agonist stimulation. TLR8 agonist combined with NA may enhance the antiviral effect of NK cells.

Keywords: IFN-γ; IL-10; TLR8; chronic hepatitis B; natural killer cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / metabolism
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • Hepatitis B, Chronic*
  • Humans
  • Interferon-gamma / metabolism
  • Interferon-gamma / pharmacology
  • Interleukin-10
  • Interleukin-12 / metabolism
  • Interleukin-12 / pharmacology
  • Interleukin-12 / therapeutic use
  • Interleukin-18
  • Killer Cells, Natural / metabolism
  • Monocytes* / metabolism
  • Toll-Like Receptor 8 / agonists
  • Toll-Like Receptor 8 / metabolism
  • Toll-Like Receptor 8 / therapeutic use

Substances

  • Antiviral Agents
  • Interferon-gamma
  • Interleukin-10
  • Interleukin-12
  • Interleukin-18
  • TLR8 protein, human
  • Toll-Like Receptor 8
  • IFNG protein, human